The psoriatic keratinocytes

References

• Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int. J. Med. Sci. 7(5), 284–289 (2010).
   PubMed Web of Science ®Google Scholar
• KaplanMJ. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc. Health Risk Manag. 4(6), 1229–1235 (2008).
   PubMedGoogle Scholar
• Sabat R, Sterry W, Philipp S, Wolk K. Three decades of psoriasis research: where has it led us? Clin. Dermatol. 25(6), 504–509 (2007).
   PubMed Web of Science ®Google Scholar
• Kanamori H, Tanaka M, Kawaguchi H et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am. J. Hematol. 71(1), 41–44 (2002).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256(22), 3110–3116 (1986).
   PubMed Web of Science ®Google Scholar
• Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1(5), 442–447 (1995).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Voorhees JJ, Nickoloff BJ. γ-Interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-I (ICAM-I) antigens. Br. J. Dermatol. 120(1), 1–8 (1989).
   Web of Science ®Google Scholar
• Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102(2), 145–149 (1994).
   PubMed Web of Science ®Google Scholar
• Bata-Csörgö Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95(1), 317–327 (1995).
   PubMed Web of Science ®Google Scholar
• Bata-Csörgö Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J. Invest. Dermatol. 105(Suppl. 1), 89S–94S (1995).
   PubMed Web of Science ®Google Scholar
• Krueger JG, Walters IB, Miyazawa M et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43(3), 448–458 (2000).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345(4), 248–255 (2001).
   PubMed Web of Science ®Google Scholar
• Krueger GG. Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis. Expert Opin. Biol. Ther. 2(4), 431–441 (2002).
   PubMed Web of Science ®Google Scholar
• Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98(8), 1878–1887 (1996).
   PubMed Web of Science ®Google Scholar
• Clark RA, Chong B, Mirchandani N et al. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176(7), 4431–4439 (2006).
   PubMed Web of Science ®Google Scholar
• Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. 199(5), 731–736 (2004).
   PubMed Web of Science ®Google Scholar
• Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11(1), 43–49 (2005).
   PubMed Web of Science ®Google Scholar
• Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437(7057), 369–375 (2005).
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell. Mol. Immunol. 9(4), 302–309 (2012).
   PubMed Web of Science ®Google Scholar
• Eyerich S, Eyerich K, Pennino D et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 119(12), 3573–3585 (2009).
   PubMed Web of Science ®Google Scholar
• Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174(6), 3695–3702 (2005).
   PubMed Web of Science ®Google Scholar
• Bos JD. Psoriasis, innate immunity, and gene pools. J. Am. Acad. Dermatol. 56(3), 468–471 (2007).
   Google Scholar
• Pellegrini G, De Luca M, Orecchia G et al. Expression, topography, and function of integrin receptors are severely altered in keratinocytes from involved and uninvolved psoriatic skin. J. Clin. Invest. 89(6), 1783–1795 (1992).
   PubMed Web of Science ®Google Scholar
• Bata-Csörgö Z, Cooper KD, Ting KM, Voorhees JJ, Hammerberg C. Fibronectin and α5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J. Clin. Invest. 101(7), 1509–1518 (1998).
   PubMed Web of Science ®Google Scholar
• Széll M, Bata-Csörgö Z, Koreck A et al. Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J. Invest. Dermatol. 123(3), 537–546 (2004).
   Google Scholar
• Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276(13), 10229–10233 (2001).
   PubMed Web of Science ®Google Scholar
• Kornblihtt AR, Pesce CG, Alonso CR et al. The fibronectin gene as a model for splicing and transcription studies. FASEB J. 10(2), 248–257 (1996).
   PubMedGoogle Scholar
• Baelde HJ, Eikmans M, van Vliet AI, Bergijk EC, de Heer E, Bruijn JA. Alternatively spliced isoforms of fibronectin in immune-mediated glomerulosclerosis: the role of TGFβ and IL-4. J. Pathol. 204(3), 248–257 (2004).
   PubMed Web of Science ®Google Scholar
• Elder JT, Bruce AT, Gudjonsson JE et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 130(5), 1213–1226 (2010).
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327(5969), 1098–1102 (2010).
   PubMed Web of Science ®Google Scholar
• Han G, Li F, Singh TP, Wolf P, Wang XJ. The proinflammatory role of TGFβ1: a paradox? Int. J. Biol. Sci. 8(2), 228–235 (2012).
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174(1), 164–173 (2005).
   PubMed Web of Science ®Google Scholar
• Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J. Cell Biol. 139(1), 295–307 (1997).
   PubMed Web of Science ®Google Scholar
• Manabe R, Oh-e N, Sekiguchi K. Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J. Biol. Chem. 274(9), 5919–5924 (1999).
   PubMedGoogle Scholar
• Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins α 9β 1 and α 4β 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J. Biol. Chem. 277(17), 14467–14474 (2002).
   PubMed Web of Science ®Google Scholar
• Sandig H, McDonald J, Gilmour J, Arno M, Lee TH, Cousins DJ. Fibronectin is a TH1-specific molecule in human subjects. J. Allergy Clin. Immunol. 124(3), 528–535, 535.e1 (2009).
   Google Scholar
• Yarovinsky TO, Monick MM, Hunninghake GW. Integrin receptors are crucial for the restimulation of activated T lymphocytes. Am. J. Respir. Cell Mol. Biol. 28(5), 607–615 (2003).
   Google Scholar
• Monick MM, Powers L, Butler N, Yarovinsky T, Hunninghake GW. Interaction of matrix with integrin receptors is required for optimal LPS-induced MAP kinase activation. Am. J. Physiol. Lung Cell Mol. Physiol. 283(2), L390–L402 (2002).
   PubMed Web of Science ®Google Scholar
• Conrad C, Boyman O, Tonel G et al. α1β1 Integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13(7), 836–842 (2007).
   PubMed Web of Science ®Google Scholar
• Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 11(3), 221–230 (2011).
   PubMed Web of Science ®Google Scholar
• Albanesi C, Pastore S. Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. Curr. Drug Metab. 11(3), 210–227 (2010).
   PubMed Web of Science ®Google Scholar
• McFadden JP, Baker BS, Powles AV, Fry L. Psoriasis and extra domain A fibronectin loops. Br. J. Dermatol. 163(1), 5–11 (2010).
   Web of Science ®Google Scholar
• Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 83(6), 957–968 (1995).
   PubMed Web of Science ®Google Scholar
• Pivarcsi A, Széll M, Kemény L, Dobozy A, Bata-Csörgö Z. Serum factors regulate the expression of the proliferation-related genes α5 integrin and keratin 1, but not keratin 10, in HaCaT keratinocytes. Arch. Dermatol. Res. 293(4), 206–213 (2001).
   Google Scholar
• Paramio JM, Casanova ML, Segrelles C, Mittnacht S, Lane EB, Jorcano JL. Modulation of cell proliferation by cytokeratins K10 and K16. Mol. Cell. Biol. 19(4), 3086–3094 (1999).
   PubMedGoogle Scholar
• Guo L, Yu QC, Fuchs E. Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. EMBO J. 12(3), 973–986 (1993).
   PubMed Web of Science ®Google Scholar
• Finch PW, Murphy F, Cardinale I, Krueger JG. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am. J. Pathol. 151(6), 1619–1628 (1997).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Jorgensen CM. Experimental models for psoriasis. J. Invest. Dermatol. 95(Suppl. 5), 56S–58S (1990).
   Google Scholar
• Andreadis ST, Hamoen KE, Yarmush ML, Morgan JR. Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system. FASEB J. 15(6), 898–906 (2001).
   PubMed Web of Science ®Google Scholar
• Koria P, Andreadis ST. KGF promotes integrin α5 expression through CCAAT/enhancer-binding protein-β. Am. J. Physiol., Cell Physiol. 293(3), C1020–C1031 (2007).
   PubMed Web of Science ®Google Scholar
• Hambalko S, Belso N, Szell M, Kemeny L, Bata-Csörgö Z. Psoriatic keratinocytes differ in α 5 integrin response from healthy keratinocytes. J. Invest. Dermatol. 129S54 (2009).
   Google Scholar
• Nagy N, Bata-Csörgö Z, Kopasz N et al. The expression of keratinocyte growth factor receptor (FGFR2-IIIb) correlates with the high proliferative rate of HaCaT keratinocytes. Exp. Dermatol. 15(8), 596–605 (2006).
   Google Scholar
• Kovacs D, Falchi M, Cardinali G et al. Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis. Exp. Dermatol. 14(2), 130–137 (2005).
   PubMed Web of Science ®Google Scholar
• Hambalko S, Bebes A, Belso N et al. KGF and KGFR expression and its changes induced by slight injury differ in normal appearing (uninvolved) skin of psoriatic patients compared to healthy skin. J. Invest. Dermatol. 130S87(2010).
   Google Scholar
• Konstantinova NV, Duong DM, Remenyik E, Hazarika P, Chuang A, Duvic M. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J. Invest. Dermatol. 107(4), 615–621 (1996).
   PubMed Web of Science ®Google Scholar
• Xu N, Brodin P, Wei T et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J. Invest. Dermatol. 131(7), 1521–1529 (2011).
   PubMed Web of Science ®Google Scholar
• Krek A, Grün D, Poy MN et al. Combinatorial microRNA target predictions. Nat. Genet. 37(5), 495–500 (2005).
   PubMed Web of Science ®Google Scholar
• Bill HM, Knudsen B, Moores SL et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol. Cell. Biol. 24(19), 8586–8599 (2004).
   PubMed Web of Science ®Google Scholar
• Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol. 128(6), 1365–1374 (2008).
   PubMed Web of Science ®Google Scholar
• Roupé KM, Nybo M, Sjöbring U, Alberius P, Schmidtchen A, Sørensen OE. Injury is a major inducer of epidermal innate immune responses during wound healing. J. Invest. Dermatol. 130(4), 1167–1177 (2010).
   PubMedGoogle Scholar
• Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J. Invest. Dermatol. 131(2), 329–337 (2011).
   Google Scholar
• Belsõ N, Széll M, Pivarcsi A et al. Differential expression of D-type cyclins in HaCaT keratinocytes and in psoriasis. J. Invest. Dermatol. 128(3), 634–642 (2008).
   Google Scholar
• Xu X, Lyle S, Liu Y, Solky B, Cotsarelis G. Differential expression of cyclin D1 in the human hair follicle. Am. J. Pathol. 163(3), 969–978 (2003).
   PubMedGoogle Scholar
• Bata-Csörgö Z, Hammerberg C, Voorhees JJ, Cooper KD. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J. Exp. Med. 178(4), 1271–1281 (1993).
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12(22), 3499–3511 (1998).
   PubMed Web of Science ®Google Scholar
• Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum. Mol. Genet. 15(17), 2553–2559 (2006).
   PubMed Web of Science ®Google Scholar
• Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 1, e128 (2006).
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 β pathway and is antagonized by insulin-like growth factor 1. J. Biol. Chem. 282(6), 3799–3808 (2007).
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Ochiya T, Takeshita F et al. Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res. 62(6), 1641–1647 (2002).
   PubMedGoogle Scholar
• Capon F, Bijlmakers MJ, Wolf N et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum. Mol. Genet. 17(13), 1938–1945 (2008).
   PubMed Web of Science ®Google Scholar
• Kanie T, Onoyama I, Matsumoto A et al. Genetic re-evaluation of the role of F-box proteins in cyclin D1 degradation. Mol. Cell. Biol. 32(3), 590–605 (2012).
   PubMedGoogle Scholar
• Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30(8), 383–391 (2009).
   PubMed Web of Science ®Google Scholar
• Zenz R, Wagner EF. Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int. J. Biochem. Cell Biol. 38(7), 1043–1049 (2006).
   PubMed Web of Science ®Google Scholar
• Smola H, Thiekötter G, Fusenig NE. Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. J. Cell Biol. 122(2), 417–429 (1993).
   PubMed Web of Science ®Google Scholar
• Maas-Szabowski N, Shimotoyodome A, Fusenig NE. Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism. J. Cell. Sci. 112(Pt. 12), 1843–1853 (1999).
   PubMed Web of Science ®Google Scholar
• Szabowski A, Maas-Szabowski N, Andrecht S et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal–epidermal interaction in skin. Cell 103(5), 745–755 (2000).
   PubMed Web of Science ®Google Scholar
• Jesus AA, Osman M, Silva CA et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 63(12), 4007–4017 (2011).
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89(3), 432–437 (2011).
   PubMed Web of Science ®Google Scholar
• Muhr P, Zeitvogel J, Heitland I, Werfel T, Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br. J. Dermatol. 165(1), 189–193 (2011).
   PubMed Web of Science ®Google Scholar
• Segre JA. Epidermal barrier formation and recovery in skin disorders. J. Clin. Invest. 116(5), 1150–1158 (2006).
   PubMed Web of Science ®Google Scholar
• Djalilian AR, McGaughey D, Patel S et al. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J. Clin. Invest. 116(5), 1243–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Madonna S, Scarponi C, Sestito R, Pallotta S, Cavani A, Albanesi C. The IFN-γ-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J. Immunol. 185(4), 2467–2481 (2010).
   PubMed Web of Science ®Google Scholar
• Schönefuss A, Wendt W, Schattling B et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp. Dermatol. 19(8), e80–e88 (2010).
   PubMed Web of Science ®Google Scholar
• McKenzie RC, Sabin E. Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp. Dermatol. 12(4), 337–345 (2003).
   PubMed Web of Science ®Google Scholar
• Wood LC, Feingold KR, Sequeira-Martin SM, Elias PM, Grunfeld C. Barrier function coordinately regulates epidermal IL-1 and IL-1 receptor antagonist mRNA levels. Exp. Dermatol. 3(2), 56–60 (1994).
   Google Scholar
• Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J. Clin. Invest. 90(2), 482–487 (1992).
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30(4), 535–546 (1994).
   PubMed Web of Science ®Google Scholar
• de Cid R, Riveira-Munoz E, Zeeuwen PL et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat. Genet. 41(2), 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Huang W, Yang S et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat. Genet. 41(2), 205–210 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu S, Dickinson D, Borke J et al. Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways and reduces psoriasiform lesions in the flaky skin mouse model. Exp. Dermatol. 16(8), 678–684 (2007).
   PubMed Web of Science ®Google Scholar
• Demerjian M, Hachem JP, Tschachler E et al. Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am. J. Pathol. 172(1), 86–97 (2008).
   PubMedGoogle Scholar
• Strange A, Capon F, Spencer CC et al. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42(11), 985–990 (2010).
   PubMed Web of Science ®Google Scholar
• Swindell WR, Johnston A, Carbajal S et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE 6(4), e18266 (2011).
   PubMed Web of Science ®Google Scholar
• Margadant C, Sonnenberg A. Integrin-TGF-β cross talk in fibrosis, cancer and wound healing. EMBO Rep. 11(2), 97–105 (2010).
   PubMed Web of Science ®Google Scholar
• Ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 109(2), 903–914 (1989).
   PubMed Web of Science ®Google Scholar
• Hu Y, Liang D, Li X et al. The role of interleukin-1 in wound biology. Part II: In vivo and human translational studies. Anesth. Analg. 111(6), 1534–1542 (2010).
   PubMed Web of Science ®Google Scholar
• Roupe KM, Nybo M, Sjobring U et al. Injury is a major inducer of epidermal innate immune responses during wound healing. J. Invest. Dermatol. 130(4), 1167–1177 (2010).
   PubMedGoogle Scholar
• Weatherhead SC, Farr PM, Jamieson D et al. Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J. Invest. Dermatol. 131(9), 1916–1926 (2011).
   PubMed Web of Science ®Google Scholar
• Hartman M, Prins M, Swinkels OQ et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br. J. Dermatol. 147(3), 538–544 (2002).
   PubMed Web of Science ®Google Scholar